The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Atypical Fractures Associated with Bisphosphonates

Atypical Fractures Associated with Bisphosphonates

November 1, 2014 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide (TCA) targeting moderate-to-severe osteoarthritis (OA) pain. The Food and Drug Administration (FDA) has put patient enrollment in a Phase 2b safety and tolerability study on a clinical hold due to the development of a knee joint infection, which occurred in one enrolled patient.1 In a completed Phase 2b dose-ranging trial, clinically meaningful and significantly better pain relief was obtained with FX006 versus the current injectable standard of care, immediate-release TCA. In addition, synovial fluid pharmacokinetic studies following a single intra-articular injection of FX006 showed therapeutic concentrations of the drug in joint fluid for at least 12 weeks.2 A Phase 3 international, multi-center, randomized, blinded, single-dose study in 462 patients with OA of the knee is planned. The study will have three arms, a 40 mg dose of FX006, placebo and a 40 mg dose of immediate-release TCA. The primary objective of this trial is planned to provide the second pivotal efficacy dataset against placebo at 12 weeks before submitting a New Drug Application (NDA). The trial will provide a key comparative dataset against immediate-release TCA. Anticipated NDA filing could be in 2016.

You Might Also Like
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • A&R and AC&R Abstracts: Bisphosphonates
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
Explore This Issue
November 2014
Also By This Author
  • Medication Preferences & Current Practices for PsA

Odanacatib is a once-weekly cathepsin K inhibitor, which is currently in Phase 3 clinical trials to treat postmenopausal osteoporosis.3 The Long-Term Odanacatib Fracture Trial (LOFT) randomized 16,713 women age 65 years and older who had a diagnosis of osteoporosis and had become menopausal at least five years prior. All women received vitamin D 5,600 IU a week and up to 1,200 mg/day of calcium. Patients were randomized to receive weekly odanacatib 50 mg (n=8,357) or placebo (n=8,356). Odanacatib-treated patients had a 54% relative risk reduction of new and worsening radiographically assessed vertebral fractures, a 47% relative risk reduction of clinical hip fractures, a 23% relative risk reduction of clinical nonvertebral fractures and a 72% relative risk reduction of clinical vertebral fractures (P<0.001 for all). Progressive increases in bone mineral density (BMD) were seen over five years in the total hip and lumbar spine. The change in BMD from baseline at Year 5 was 9.5% for total hip and 11.2% for lumbar spine (P<0.001 for both).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the odanacatib-treated group, 12 patients developed morphea-like skin lesions that resolved or improved following drug discontinuation. According to the Mayo Clinic, morphea is a localized or limited form of scleroderma, which usually appears on the abdomen, but can affect the face (which can make patients concerned about their appearance), arms and legs.4

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Safety, Soft Tissue Pain Tagged With: Bisphosphonate, drug, Fibromyalgia, Fractures, FX006, Kaufman, odanacatib, Osteoporosis, osteoporosis treatments, rheumatology, SafetyIssue: November 2014

You Might Also Like:
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • A&R and AC&R Abstracts: Bisphosphonates
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
  • Denosumab Linked to Rebound-Associated Fractures in Nine Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)